Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Final analysis of ELOQUENT-2: QoL in RRMM with elotuzumab plus Ld

Ravi Vij • 7 Dec 2019
ASH 2019
Multiple Myeloma Antibodies Dexamethasone Elotuzumab Lenalidomide
ELOQUENT-2

Ravi Vij, MD, MBA, Washington University School of Medicine, Saint Louis, MO, outlines the final analysis of patient-reported outcomes data from ELOQUENT-2 study (NCT01239797) of elotuzumab plus lenalidomide/dexamethasone (Ld) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This final analysis confirms that the efficacy benefits observed with addition of elotuzumab to Ld in patients with R/R MM were achieved without negatively affecting health-related quality of life compared with Ld. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Ravi Vij

2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
3:23
Updated safety and efficacy results of Abbv-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals